Spironolactone and Insulin Resistance in Chronic Heart Failure (CHF)

This study has been completed.

First Received: April 18, 2008 Last Updated: April 21, 2008 History of Changes

Sponsored by:	Tottori University Hospital
Information provided by:	Tottori University Hospital
ClinicalTrials.gov Identifier:	NCT00664222

Purpose

The purpose of this study is to evaluate the effects of spironolactone and furosemide on insulin resistance in patients with chronic heart failure.

Condition	Intervention	Phase
Chronic Stable Heart Failure	Drug: spironolactone + furosemide	Phase IV

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Crossover Assignment, Efficacy Study
Official Title:	Effects of Spironolactone on Insulin Resistance in Patients With Chronic Heart Failure

Resource links provided by NLM:

MedlinePlus related topics: Heart Failure

Drug Information available for: Spironolactone Furosemide Insulin

U.S. FDA Resources

Further study details as provided by Tottori University Hospital:

Primary Outcome Measures:

insulin resistance [ Time Frame: 16 weeks ]

Enrollment:	16
Study Start Date:	January 2004
Estimated Study Completion Date:	December 2005

Intervention Details:

spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16weeks

Detailed Description:

Diuretics is useful in CHF patients. On the other hand, they deteriorate glucose metabolism. Therefore, the purpose of this study is to evaluate the effects of spironolactone and furosemide on insulin resistance in patients with chronic heart failure.

Eligibility

Genders Eligible for Study:

Both

Criteria

Inclusion Criteria:

chronic stable heart failure

Exclusion Criteria:

renal dysfunction or under treatment with antidiabetic agents

Contacts and Locations

No Contacts or Locations Provided

More Information

No publications provided

Responsible Party:	Center for Clinical Residency Program, Tottori University Hospital ( Kazuhide Ogino, MD )
Study ID Numbers:	#344.1
Study First Received:	April 18, 2008
Last Updated:	April 21, 2008
ClinicalTrials.gov Identifier:	NCT00664222 History of Changes
Health Authority:	Japan: Ministry of Health, Labor and Welfare

Keywords provided by Tottori University Hospital:

heart failure
insulin resistance
inflammatory cytokine
spironolactone
furosemide

Study placed in the following topic categories:

Heart Failure
Heart Diseases
Metabolic Diseases
Hormone Antagonists
Diuretics
Hormones, Hormone Substitutes, and Hormone Antagonists
Cardiovascular Agents
Hormones
Furosemide

Insulin
Spironolactone
Hyperinsulinism
Aldosterone Antagonists
Insulin Resistance
Glucose Metabolism Disorders
Sodium Potassium Chloride Symporter Inhibitors
Metabolic Disorder

Additional relevant MeSH terms:

Heart Failure
Heart Diseases
Metabolic Diseases
Molecular Mechanisms of Pharmacological Action
Hormone Antagonists
Physiological Effects of Drugs
Diuretics
Hormones, Hormone Substitutes, and Hormone Antagonists
Cardiovascular Agents
Furosemide
Pharmacologic Actions

Spironolactone
Membrane Transport Modulators
Hyperinsulinism
Aldosterone Antagonists
Natriuretic Agents
Therapeutic Uses
Cardiovascular Diseases
Insulin Resistance
Glucose Metabolism Disorders
Sodium Potassium Chloride Symporter Inhibitors

ClinicalTrials.gov processed this record on July 02, 2009